26 March 2021 - If approved by the European Commission, enzalutamide will be the only oral therapy for the treatment of metastatic hormone-sensitive prostate cancer in addition to non-metastatic and metastatic castration-resistant prostate cancer.

Astellas announced today the CHMP of the EMA has adopted a positive opinion recommending an additional indication for the oral once-daily therapy Xtandi (enzalutamide) for adult men with metastatic hormone-sensitive prostate cancer (also known as metastatic castration-sensitive prostate cancer).

Read Astellas press release